Imiquimod

Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Retrieved on: 
Wednesday, December 27, 2023
Liver, RNA interference, LNC, Small RNA, PCR, DSS, Inflammation, Serum, Animal, IL-17A, Commensurability, Colitis, Imiquimod, Lecture, Psoriasis, Oligonucleotide, Therapy, Vaccine

BEDMINSTER, N.J, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform technology, announces results from a series of in vivo studies demonstrating successful oral delivery of two LNC-formulated small single-strand oligonucleotides that specifically target key inflammatory cytokines TNFα and IL-17A in well-established and validated animal models that mimic acute inflammatory responses seen in human diseases.

Key Points: 
  • Commensurate improvements in clinical disease markers and scores were also documented in both models,” said James Ferguson, M.D., Matinas’ Chief Medical Officer .
  • “While additional study is warranted, the successful oral delivery of small oligonucleotides is very exciting and we believe these data demonstrate how Matinas’ LNC platform could be used for the oral delivery of functional small oligonucleotides with potential therapeutic applications,” Dr. Ferguson added.
  • Both were advanced to in vivo studies to evaluate meaningful biological activity in relevant disease models.
  • In this model, while IL-17A serum levels were not expected to change, improvement was demonstrated in clinical disease markers of skin redness and scaling, further validating the biological activity of these small oligonucleotides.

Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data

Retrieved on: 
Thursday, May 11, 2023
Malignancy, Central nervous system, Depression, Schizophrenia, ISID, Pathology, Psoriasis, Quality of life, IL-6, Mental, Imiquimod, CNS, RP5063, Patent, DSM-IV codes, Patient, IL-8, Comorbidity, Risk, BALB/c, Toxic encephalopathy, Serotonin, IND, Pharmaceutical industry, Dopamine, Brilaroxazine

CUPERTINO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, has presented promising preclinical data on the potential of novel serotonin-dopamine stabilizer brilaroxazine for the treatment of psoriasis at the First International Societies for Investigative Dermatology (ISID) Meeting in Tokyo, Japan, May 10-13, 2023. The ISID poster is available at revivapharma.com/publications.

Key Points: 
  • “We were excited to present encouraging preclinical data at ISID 2023 highlighting the therapeutic potential of brilaroxazine lipogel, a novel, proprietary lipogel formulation for the topical treatment of psoriasis.
  • We have filed a composition of matter patent for brilaroxazine-lipogel and a separate patent for its use in psoriasis.
  • Brilaroxazine (RP5063) is a modulator of D and 5-HT receptors with multifaceted activity that may affect underlying psoriasis pathology.
  • Preclinical studies in the imiquimod-induced psoriatic mouse model (BALB/c) were used to evaluate the potential of topical liposomal-gel formulation of brilaroxazine for the treatment of psoriasis.

Global Actinic Keratosis Treatment Market Report 2022: Featuring Key Players 3M, Bausch Health Companies, Novartis & Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 30, 2022
Market development, Sun Pharma, Observation, Hospital pharmacy, Porter's five forces analysis, Viatris, USD, Ansoff Matrix, Investment, Geography, SWOT, CAGR, Imiquimod, Hospital, Risk, COVID-19, Diclofenac, Pharmacy, BioLineRx, Growth, Industry, Retail, Risk management, Fluorouracil

The Global Actinic Keratosis Treatment Market is segmented based on Type, End-Users, and Geography.

Key Points: 
  • The Global Actinic Keratosis Treatment Market is segmented based on Type, End-Users, and Geography.
  • Ansoff Analysis The report presents a detailed Ansoff matrix analysis for the Global Actinic Keratosis Treatment Market.
  • The analyst analyses the Global Actinic Keratosis Treatment Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Actinic Keratosis Treatment Market.

New Sales Leadership Joins HealthEdge to Accelerate Growth and Support the Expansion of Digital Health Platform

Retrieved on: 
Wednesday, June 1, 2022
Data Management, Health, Technology, Hospitals, Practice Management, Managed Care, Software, Leadership, Cognizant, Research, Cigna, LinkedIn, SVP, Senior, Multimedia, Growth, Publication, Technology, Adoption, Twitter, Software as a service, Xerox, Management, Software, Gartner, Imiquimod

HealthEdge announced two strategic additions to its sales leadership: Matt Francis, Senior Vice President, HealthRules Payor Sales, and Jeff Jacobs, Senior Vice President, Source Sales.

Key Points: 
  • HealthEdge announced two strategic additions to its sales leadership: Matt Francis, Senior Vice President, HealthRules Payor Sales, and Jeff Jacobs, Senior Vice President, Source Sales.
  • They will be responsible for driving new customer growth and adoption of the HealthEdge Digital Platform, a suite of cloud-based SaaS applications for core administration ( HealthRules Payor ), payment integrity ( Source ), care management ( GuidingCare ), and digital health management ( Wellframe ).
  • The expansion of the sales team will enable the company to meet the increasing demands of regional and national health plan customers.
  • He will support the expansion and growth of HealthEdges payment integrity platform, Source.

Pulse Biosciences to Present New Data on Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia and for Focal Epithelial Hyperplasia at 2022 American Society of Laser Medicine and Surgery Annual Conference

Retrieved on: 
Tuesday, April 26, 2022
Biotechnology, Health, Medical Devices, Society, Sebaceous hyperplasia, Mouth, Recurrence, Annual general meeting, Imiquimod, NPS, MD, Science, HPV, Patient, SH, Wart, List of life sciences, Nasdaq, Skin, Papilloma, Safety, American Academy, Tretinoin, FEH, Physician, Quality of life, Medical device, Medical imaging, Health insurance, Dermatology

In a study for the treatment of Sebaceous Hyperplasia (SH), 12-month data demonstrated durable efficacy for the clearance of Sebaceous Hyperplasia lesions.

Key Points: 
  • In a study for the treatment of Sebaceous Hyperplasia (SH), 12-month data demonstrated durable efficacy for the clearance of Sebaceous Hyperplasia lesions.
  • The poster abstract on Nano-Pulse Stimulation technology showcases a case report that generated positive results of clearing refractory focal epithelial hyperplasia (FEH) on the lips with the NPS procedure.
  • Pulse Biosciences also announced the debut of its first U.S. exhibit at the ASLMS annual meeting.
  • The Companys proprietary Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue.

UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer

Retrieved on: 
Tuesday, March 29, 2022
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Company, Private Securities Litigation Reform Act, Risk, Recurrence, Trial of the century, Immunotherapy, NMIBC, Mortality, BCG, Association, IND, SEC, Standard of care, Cancer, Food, U.S. Securities and Exchange Commission, Neoplasm, Mitomycins, Immune system, Urinary bladder, Safety, Technology, Twitter, Nasdaq, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Toxic leukoencephalopathy, TLR7, Bladder cancer, Efficiency, FDA, TURBT, Patient, HG, Security (finance), Imiquimod, Pharmaceutical industry, Medical imaging

UroGen initially plans to combine UGN-301 with UGN-201, the Companys proprietary formulation of imiquimod a toll-like receptor 7 (TLR7) agonist, which has demonstrated single-agent activity in high-risk bladder cancer patients.

Key Points: 
  • UroGen initially plans to combine UGN-301 with UGN-201, the Companys proprietary formulation of imiquimod a toll-like receptor 7 (TLR7) agonist, which has demonstrated single-agent activity in high-risk bladder cancer patients.
  • The novel study design will utilize a Master Protocol that UroGen believes is a more efficient and streamlined approach to development.
  • Bladder cancers are described as muscle invasive or non-muscle invasive based on whether they have invaded the wall of the bladder.
  • HG NMIBC patient response to BCG therapy has long been interpreted as evidence that bladder cancer is sensitive to immunotherapy.

Results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published

Retrieved on: 
Thursday, November 18, 2021
Patient, Skin, Trial of the century, JM, CTCL, T-cell lymphoma, Neoplasm, HDAC, Partnership, SCC, Stanford University School of Medicine, Basal-cell carcinoma, Cancer, Stanford University, Nasdaq Stockholm, Human, Leadership, Squamous cell carcinoma, SCCS, Nasdaq, Imiquimod, Dermatology, Itch, Kilgour, Market capitalization, BCC, SMAC, Drug development, ORR, JAMA Dermatology, Pharmaceutical industry

STOCKHOLM, Nov. 18, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)today announces that results from the investigator-initiated phase II clinical study in patients with squamous cell carcinoma (SCC) has been published in JAMA Dermatology by Kilgour, JM et al (doi:10.1001/jamadermatol.2021.4549).

Key Points: 
  • STOCKHOLM, Nov. 18, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)today announces that results from the investigator-initiated phase II clinical study in patients with squamous cell carcinoma (SCC) has been published in JAMA Dermatology by Kilgour, JM et al (doi:10.1001/jamadermatol.2021.4549).
  • Medivir is providing remetinostat drug supply for this study, and has full access to, and the rights to use, all clinical data after the study is complete.
  • Four patients with five biopsy-proven cutaneous SCCs were included in this case series and treated with remetinostat gel 1%.
  • In addition, two investigator-initiated phase II studies have been conducted at Stanford University in the USA, demonstrating efficacy in both Basal Cell Carcinoma (BCC) and cutaneous Squamous Cell Carcinoma (SCC).

Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical Studies

Retrieved on: 
Tuesday, October 26, 2021
Animal, Elasticity, Human, Phenotype, Reactive neutrophilic dermatoses, Research, Inflammation, Regulation, Imiquimod, Pathology, Twitter, Skin, Patient, Cytokine, U.S. Securities and Exchange Commission, Regulation Fair Disclosure, T helper 17 cell, Degenerative disease, Atrophoderma, Protein, Disclosure, Biomarker, IL-6, BET, CXCL10, Cyprus Securities and Exchange Commission, Nasdaq, Therapy, D, Method, GLOBE, Erythema, Mouse, Cosmetics, Pharmaceutical industry, Phosphorus

We are encouraged by the evolving therapeutic profile of our lead topical BET inhibitor, VYN201, said David Domzalski, VYNEs Chief Executive Officer.

Key Points: 
  • We are encouraged by the evolving therapeutic profile of our lead topical BET inhibitor, VYN201, said David Domzalski, VYNEs Chief Executive Officer.
  • VYN201 is a first-in-class topical soft pan-bromodomain BET inhibitor that is designed to control multiple pro-inflammatory pathways while mitigating systemic drug exposure.
  • Key findings from the study:
    A dose-dependent improvement in the signs and symptoms of inflammation was observed for VYN201 treatment groups.
  • As epigenetic readers, BET proteins regulate the recruitment of transcriptional factors that are key to the production of several pro-inflammatory cytokines.

Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference

Retrieved on: 
Tuesday, January 19, 2021
Medical specialties, Virology, Clinical medicine, Infectious causes of cancer, EGW, Molluscum contagiosum, Wart, Genital wart, Dermatology, Imiquimod, Koebner phenomenon

The data were presented in poster format online for the 2021 Winter Clinical Dermatology Conference.

Key Points: 
  • The data were presented in poster format online for the 2021 Winter Clinical Dermatology Conference.
  • VP-102, our lead candidate, continues to demonstrate positive results as we advance development of the program in molluscum, external genital warts and common warts, three of the largest unmet needs in medical dermatology.
  • Data were also presented from Verricas Phase 2 CARE-1 clinical study of VP-102 in external genital warts (EGW).
  • Verricas late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and external genital warts, three of the largest unmet needs in medical dermatology.

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Retrieved on: 
Wednesday, December 23, 2020
Medical specialties, Virology, Clinical medicine, Molluscum contagiosum, Poxviruses, Infectious causes of cancer, Cantharidin, Wart, Genital wart, Plantar wart, Imiquimod, Molluscum dermatitis

We look forward to working with the FDA through the review process, and if approved, bringing VP-102 to patients as the first FDA-approved treatment option for molluscum.

Key Points: 
  • We look forward to working with the FDA through the review process, and if approved, bringing VP-102 to patients as the first FDA-approved treatment option for molluscum.
  • Without treatment, molluscum can last for an average of 13 months, and in some cases, up to several years.
  • Verricas late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and external genital warts, three of the largest unmet needs in medical dermatology.
  • Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts.